Allogeneic Expanded Gamma Delta T Cells with GD2 Chemoimmunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic Expanded Gamma Delta T Cells with GD2 Chemoimmunotherapy, covering 2025-12-26 to 2025-12-26. Get the full timeline:
Most recent: Clinical Trial Update: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma [Phase 1]